During the recent session, Abbvie Inc (NYSE:ABBV)’s traded shares were 1.93 million, with the beta value of the company hitting 0.62. At the last check today, the stock’s price was $205.05, reflecting an intraday gain of 1.76% or $3.55. The 52-week high for the ABBV share is $202.35, that puts it up 1.32 from that peak though still a striking 33.75% gain since the share price plummeted to a 52-week low of $135.85. The company’s market capitalization is $362.19B, and the average intraday trading volume over the past 10 days was 5.57 million shares, and the average trade volume was 4.74 million shares over the past three months.
Abbvie Inc (ABBV) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.84. ABBV has a Sell rating from 0 analyst(s) out of 27 analysts who have looked at this stock. 7 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 20 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 2.95.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Abbvie Inc (NYSE:ABBV) trade information
Abbvie Inc (ABBV) registered a 1.76% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 1.76% in intraday trading to $205.05, hitting a weekly high. The stock’s 5-day price performance is 8.12%, and it has moved by 4.18% in 30 days. Based on these gigs, the overall price performance for the year is 45.24%. The short interest in Abbvie Inc (NYSE:ABBV) is 16.18 million shares and it means that shorts have 3.56 day(s) to cover.
The consensus price target of analysts on Wall Street is $172, which implies a decrease of -19.22% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $127 and $228 respectively. As a result, ABBV is trading at a discount of -11.19% off the target high and 38.06% off the low.
Abbvie Inc (ABBV) estimates and forecasts
Statistics show that Abbvie Inc has underperformed its competitors in share price, compared to the industry in which it operates. Abbvie Inc (ABBV) shares have gone up 27.51% during the last six months, with a year-to-date growth rate less than the industry average at -2.34% against 8.10. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 5.70% this quarter and then jump 13.00% in the quarter after that. In the rating firms’ projections, revenue will increase 2.80% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 14.75B as predicted by 15 analyst(s). Meanwhile, a consensus of 5 analyst(s) estimates revenue growth to 13.22B by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 14.3B and 12.31B respectively. In this case, analysts expect current quarter sales to grow by 3.20% and then jump by 7.40% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -5.77%. While earnings are projected to return -1.94% in 2024, the next five years will return 7.75% per annum.
ABBV Dividends
Abbvie Inc is due to release its next quarterly earnings on 2025-Jan-31. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance. Investors should also take the other fundamental and operational aspects into account before investing in the stock. The forward dividend ratio for Abbvie Inc is 6.20, with the dividend yield indicating at 3.02 percent, continuing the trend of increasing dividends in recent years. The average dividend yield of the company for the last 5 years is 4.19%.
Abbvie Inc (NYSE:ABBV)’s Major holders
Abbvie Inc insiders own 0.09% of total outstanding shares while institutional holders control 73.49%, with the float percentage being 73.56%. VANGUARD GROUP INC is the largest shareholder of the company, while 4190.0 institutions own stock in it. As of 2024-06-30, the company held over 170.66 million shares (or 9.6472% of all shares), a total value of $29.27 billion in shares.
The next largest institutional holding, with 136.43 million shares, is of BLACKROCK INC.’s that is approximately 7.7124% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $23.4 billion.
